Palau Science & Technology Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Palau Science & Technology Journal.

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Press releases published on January 30, 2026

Jan. 30, 2026

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

GlobeNewswire

Jan. 30, 2026

Russian Sandworm group attacks energy company in Poland with DynoWiper, ESET Research discovers

GlobeNewswire

Jan. 30, 2026

Award-winning HR Software HiBob Ranked #25 on Accadian Ventures’ Future of Work 100 – 2025

GlobeNewswire

Jan. 30, 2026

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

GlobeNewswire

Jan. 30, 2026

Legion letter to Prime Minister: On sovereignty, freedom, and Afghanistan

GlobeNewswire

Jan. 30, 2026

Lettre de la Légion au Premier ministre : Sur la souveraineté, la liberté, et l’Afghanistan

GlobeNewswire

Jan. 30, 2026

CallRevu Elevates Dealership Communications with DylanAI, a Major Phone System Upgrade as a New Level of AI Receptionist for Automotive

GlobeNewswire

Jan. 30, 2026

iChatGo: AI-Driven Web3 Search Engine Decentralized Information Ecosystem

GlobeNewswire

Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

GlobeNewswire

Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

GlobeNewswire

Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

GlobeNewswire

Jan. 30, 2026

Quantexa als führendes Unternehmen im Gartner® Magic Quadrant™ 2026 für Decision Intelligence-Plattformen ausgezeichnet

GlobeNewswire

Jan. 30, 2026

Quantexa reconnu comme Leader dans le 2026 Gartner® Magic Quadrant™ for Decision Intelligence Platforms

GlobeNewswire

Jan. 30, 2026

Exterro renforce la protection des données et la confiance de ses clients grâce à l’obtention de la certification ISO 27001

GlobeNewswire

Jan. 30, 2026

Exterro stärkt Kundendatenschutz und -vertrauen mit ISO 27001-Zertifizierung

GlobeNewswire

Jan. 30, 2026

VivoPower to Present at the Noble Capital Markets Emerging Growth Virtual Conference

GlobeNewswire

Jan. 30, 2026

NordVPN’s Threat Protection Pro™ ranks fourth in an independent anti-phishing test

GlobeNewswire

Jan. 30, 2026

Gainwell Convenes State, Provider, and Policy Leaders on Strengthening Medicaid Provider Networks

GlobeNewswire

Jan. 30, 2026

Robust Growth Expected in Consumer AR Glasses as Shipments Near 30 Million by 2030, Driven by No-Display Designs

GlobeNewswire

Jan. 30, 2026

ACTFORE Secures Patent for Template Identification and Matching Technology, Transforming Large-Scale Document Analysis in Breach Response

GlobeNewswire